 LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 GLOBE NEWSWIRE -- Mereo BioPharma Group plc NASDAQ: MREO, Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Companys Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereos Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, MA advisory and value management. 